PMGC Holdings Inc. (ELAB): R&D Expense
$147.0K
Year ended 2025-12-31
$405.2K
Trailing 12 months to 2026-06-30
-13.7%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $147.0K | +40.5% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $104.7K | n/m | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $7.4K | -96.8% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $228.7K | n/a | 2024-03-29, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $147.0K | +40.5% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $12.54M | -24.3% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $19.24M | -37.8% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $67.75M | -0.2% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $30.25M | -0.6% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.91M | -14.2% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $3.61M | +18.9% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $17.77M | -15.1% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $8.24M | +249.0% |
Compare ELAB, VCNX, YARW, SLN side by side · Screen every company in Pharmaceutical Preparations ↗